Global Stem Cell Partnering 2014-2019: Deal trends, players and financials

Global Stem Cell Partnering 2014-2019: Deal trends, players and financials

The Global Stem Cell Partnering 2014-2019: Deal trends, players, financials and forecasts report provides comprehensive understanding and unprecedented access to the stem cell partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in stem cell partnering
Deal terms analysis
Partnering agreement structure
Partnering contract documents
Top deals by value
Most active dealmakers
Average deal terms for stem cells

The report provides a detailed understanding and analysis of how and why companies enter Stem Cell partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

This report provides details of the latest Stem Cell agreements announced in the life sciences since 2014.

The report takes the reader through a comprehensive review Stem Cell deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Stem Cell partnering deals.

The report presents financial deal term values for Stem Cell deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Stem Cell partnering field; both the leading deal values and most active Stem Cell dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 200 online deal records of actual Stem Cell deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Stem Cell dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Stem Cell dealmaking since 2014, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Stem Cell deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Stem Cell dealmaking with a brief summary followed by a comprehensive listing of Stem Cell deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of Stem Cell partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Stem Cell partnering deals signed and announced since Jan 2014. The chapter is organized by specific Stem Cell technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Stem Cell partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Stem Cell partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Stem Cell technologies and products.

Key benefits

Global Stem Cell Partnering 2014-2019: Deal trends, players, financials and forecasts provides the reader with the following key benefits:

In-depth understanding of Stem Cell deal trends since 2014
Access to headline, upfront, milestone and royalty data
Analysis of the structure of Stem Cell agreements with numerous real life case studies
Detailed access to actual Stem Cell contracts entered into by leading biopharma companies
Identify most active Stem Cell dealmakers since 2014
Insight into terms included in a Stem Cell partnering agreement, with real world examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Stem Cell Partnering 2014-2019: Deal trends, players, financials and forecasts is intended to provide the reader with an in-depth understanding and access to Stem Cell trends and structure of deals entered into by leading companies worldwide.

Stem Cell Partnering Terms and Agreements includes:

Trends in Stem Cell dealmaking in the biopharma industry since 2014
Analysis of Stem Cell deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life Stem Cell deals
Access to Stem Cell contract documents
Leading Stem Cell deals by value since 2014
Most active Stem Cell dealmakers since 2014

In Global Stem Cell Partnering 2014-2019: Deal trends, players, financials and forecasts, the available deals are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy target
Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Stem Cell Partnering 2014-2019: Deal trends, players, financials and forecasts report provides comprehensive access to available deals and contract documents for over 200 Stem Cell deals.

Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

  • Executive Summary
  • Introduction
  • Trends in Stem Cell dealmaking
    • Introduction
    • Stem Cell partnering over the years
    • Most active Stem Cell dealmakers
    • Stem Cell partnering by deal type
    • Stem Cell partnering by therapy area
    • Deal terms for Stem Cell partnering
      • Stem Cell partnering headline values
        • Table Stem Cell deals with a headline value
      • Stem Cell deal upfront payments
        • Table Stem Cell deals with an upfront value
      • Stem Cell deal milestone payments
        • Table Stem Cell deals with a milestone value
      • Stem Cell royalty rates
        • Table Stem Cell deals with a royalty rate value
  • Leading Stem Cell deals
    • Introduction
    • Top Stem Cell deals by value
      • Table Top Stem Cell deals by value since 2014
  • Most active Stem Cell dealmakers
    • Introduction
    • Most active Stem Cell dealmakers
    • Most active Stem Cell partnering company profiles
      • California Institute for Regenerative Medicine
      • BrainStorm Cell Therapeutics
      • Cellular Dynamics International
      • Plasticell
      • Cynata Therapeutics
      • Evotec
      • TiGenix
      • ViaCyte
      • National Institutes of Health
      • Biological Industries
      • GE Healthcare
      • Harvard Stem Cell Institute
      • Lineage Cell Therapeutics
      • National Psoriasis Foundation
      • Stemcell Technologies
      • University of California Irvine
      • AiVita Biomedical
      • Allele Biotechnology and Pharmaceuticals
      • Cellect Biotechnology
      • Cell Therapy Catapult
      • Creative Medical Technologies
      • DefiniGEN
      • Israeli National Authority for Technological Innovation
      • JCR Pharmaceuticals
      • Mesoblast
  • Stem Cell contracts dealmaking directory
    • Introduction
    • Stem Cell contracts dealmaking directory
  • Stem Cell dealmaking by technology type
    • Stem cells
  • Partnering resource center
    • Online partnering
    • Partnering events
    • Further reading on dealmaking
  • Appendices
    • Stem Cell deals by company A-Z
      • A*STAR Agency for Science, Technology and Research
      • A*STAR Genome Institute of Singapore
      • Accellta
      • Access BIO
      • Aelan Cell Technologies
      • AGC Asahi Glass
      • AiVita Biomedical
      • Akron Biotechnology
      • Allele Biotechnology and Pharmaceuticals
      • American CryoStem
      • American society of Hematology
      • Angiocrine Bioscience
      • Angionetics
      • Angiostem
      • Anthony Nolan
      • Apceth
      • Aratana Therapeutics
      • Ascendance Biotechnology
      • Astellas Pharma
      • Asterand Bioscience
      • Asterias Biotherapeutics
      • AstraZeneca
      • Athersys
      • Australian Research Council
      • Axcelead Drug Discovery Partners
      • Axiogenesis
      • AxoSim
      • Bassett Salon Solutions
      • Bayer USA Foundation
      • Baylor Research Institute
      • Beckman Research Institute of City of Hope
      • Berlin-Brandenburg Center for Regenerative Therapies
      • Beyond Type 1
      • Be The Match BioTherapies
      • Bio-Techne
      • BioBridge Global
      • BioCardia
      • BioHeart
      • Biological Industries
      • Biomed
      • BioRestorative Therapies
      • Biosafe
      • Biotech Products Services & Research
      • BlueRock Therapeutics
      • Boehringer Ingelheim
      • BrainStorm Cell Therapeutics
      • Brigham and Women's Hospital
      • Caladrius Biosciences
      • Calidi Biotherapeutics
      • California Institute for Regenerative Medicine
      • California State University
      • California Stem Cell
      • Calimmune
      • Canadian National Transplant Research Program
      • CareDx
      • Case Western Reserve University
      • CASI Pharmaceuticals
      • Catalent Pharma Solutions
      • Cedars-Sinai Medical Center
      • Celgene
      • Cell2in
      • Cellaria Biosciences
      • Cellectricon
      • Cellect Biotechnology
      • Celling Biosciences
      • CellProThera
      • Celltex Therapeutics
      • Cellular Biomedicine
      • Cellular Dynamics International
      • Cell Applications
      • Cell Care Therapeutics
      • Cell Therapy Catapult
      • Celularity
      • Censo Biotechnologies
      • Center for iPS Cells Research and Application
      • Centogene
      • Centre for Commercialization of Regenerative Medicine (CCRM)
      • Centre for Drug Research and Development (CDRD)
      • Cesca Therapeutics
      • Charite-Universitatsmedizin
      • Children's Hospital Boston
      • China Cord Blood
      • China Southeast University
      • Cincinnati Children's Hospital Medical Center
      • City of Hope
      • Clontech Laboratories
      • Cognate BioServices
      • Connecticut Innovations
      • CORD:USE
      • Cordlife
      • Cord Blood Registry
      • Creative Medical Technologies
      • CRISPR Therapeutics
      • CryoPort
      • Cynata Therapeutics
      • Dana-Farber Cancer Institute
      • DefiniGEN
      • DePuy
      • Elixirgen
      • EpiBone
      • Eppendorf
      • ERS Genomics
      • ES Cell International
      • European Union
      • Evotec
      • ExCellThera
      • Fate Therapeutics
      • Florey Institute of Neuroscience and Mental Heath
      • Florida State University
      • Fondazione San Raffaele
      • Fondazione Telethon
      • Food and Drug Administration (FDA)
      • Fortis Healthcare
      • Fraunhofer Institute for Molecular Ecology (IME)
      • Fujifilm
      • Gamida Cell
      • Genetrix
      • GenVec
      • GE Healthcare
      • Gladstone Institutes
      • GlaxoSmithKline
      • Global Alliance for Innovation in Neuroscience
      • Golden Meditech
      • Government of Canada
      • Gulf Coast Pharmaceuticals
      • Hadassah Medical Center
      • Hamad Bin Khalifa University
      • Harvard Medical School
      • Harvard Stem Cell Institute
      • Harvard University
      • HemispheRx Biopharma
      • Hepregen
      • Heraeus
      • Histogen
      • Hong Kong Baptist University
      • Horizon Discovery
      • Huapont Pharma
      • Human Life CORD Japan
      • Human Longevity
      • Icon
      • ID Pharma
      • ImmunoCellular Therapeutics
      • Indiana University
      • Inform Genomics
      • Innovate UK
      • Institute for Research in Immunology and Cancer – Commercialization of Research
      • Institute Of Molecular Biotechnology
      • IntelliCell BioSciences
      • International Stem Cell
      • InVivo Therapeutics
      • IPS Academia Japan
      • Israeli National Authority for Technological Innovation
      • Jazz Pharmaceuticals
      • JCR Pharmaceuticals
      • Johnson & Johnson Innovation
      • Johns Hopkins University
      • Kiadis Pharma
      • Kinetic River
      • Kings College London
      • Kite Pharma
      • Kyoto University
      • Laboratory Corporation of America
      • Lehigh University
      • Leiden University
      • Leona M and Harry B Helmsley Charitable Trust
      • LifeSouth Community Blood Centers
      • Lineage Cell Therapeutics
      • Longeveron
      • Lonza
      • Lupus Foundation of America (LFA)
      • Macquarie University
      • Magenta Therapeutics
      • Magnum Cell Therapies
      • Maryland Stem Cell Research Fund
      • Massachusetts General Hospital
      • Mayo Clinic
      • McGill University
      • MD Anderson Cancer Center
      • Medical Technology Enterprise Consortium
      • Memorial Sloan Kettering Cancer Center
      • Merck and Co
      • Mesoblast
      • Metrion Biosciences
      • Michael J Fox Foundation
      • Mill Creek Life Sciences
      • Miltenyi Biotec
      • Minerva Biotechnologies
      • Multiclonal Therapeutics
      • Munich Technical University
      • Murdoch Childrens Research Institute
      • Nanion
      • NanoRanch
      • Nano Dimension
      • Nanyang Technological University
      • Natera
      • National Eye Institute
      • National Heart, Lung and Blood Institute
      • National Institutes of Health
      • National Institutes of Health Center for Regenerative Medicine
      • National Institute of Allergy and Infectious Diseases
      • National Institute on Aging
      • National Psoriasis Foundation
      • National Stem Cell Foundation
      • National University of Ireland, Galway (NUI Galway)
      • Ncardia
      • Nestle Health Science
      • NetScientific
      • Nohla Therapeutics
      • Northwestern University
      • Novo Nordisk
      • Nuclea Biotechnologies
      • NuGene International
      • Ocata Therapeutics
      • Orbsen Therapeutics
      • Orchard Therapeutics
      • Organovo
      • Orgenesis
      • ORIG3N
      • Orthocell
      • OrthoCyte
      • Orthopaedic Research and Education Foundation
      • Osiris Therapeutics
      • Parcell Laboratories
      • Pathways to Stem Cell Science
      • PharmaCyte Biotech
      • Pivotal Scientific
      • Plasticell
      • Platelet BioGenesis
      • Prasco Laboratories
      • Procella Therapeutics
      • Q Therapeutics
      • Ramot at Tel Aviv University
      • Recordati
      • Regeneus
      • Regen BioPharma
      • ReNeuron
      • Renovacare
      • ReproCell
      • Research Products Development Company
      • Rockefeller University
      • Rockland Immunochemicals
      • Rohto Pharmaceutical
      • ROSLINCT
      • Royal Children's Hospital
      • Rutgers University
      • RxBio
      • Salk Institute
      • Sana Biotechnology
      • Sangamo BioSciences
      • Scaled Biolabs
      • ScinoPharm Taiwan
      • SCM Pharma
      • Scripps Research Institute
      • SeouLin Bioscience
      • Seres Therapeutics
      • Sharp Edge Labs
      • Sigma-Tau
      • Sirion Biotech
      • Small Business Innovation Research
      • Smartwise
      • Spectrum Pharmaceuticals
      • Stanford University
      • StemCell Systems
      • Stemcell Technologies
      • Stemedica Cell Technologies
      • StemExpress
      • Stemlife
      • StemoniX
      • Stem Cell Medicine
      • Stem Cell Network
      • Stryker
      • TaiGen Biotechnology
      • TaiRx
      • Takara Bio
      • Takeda Pharmaceutical
      • Targazyme
      • Taxus Cardium Pharmaceuticals
      • Technology University Dresden
      • Teijin
      • Temple University
      • Terumo BCT
      • TFS International
      • TheraBiologics
      • Therakine
      • The Global Stem Cell and Regenerative Medicine Acceleration Center (GSRAC)
      • The New York Stem Cell Foundation
      • The Regents of the University of California
      • Thomas Jefferson University
      • Thrive Bioscience
      • Tianhe Stem Cell Biotechnologies
      • TiGenix
      • Tissue Genesis
      • Tiziana Life Sciences
      • TTFactor
      • Tu Dresden
      • University Ann & Robert H. Lurie Children's Hospital
      • University City Science Center
      • University College London
      • University Health Network
      • University of Adelaide
      • University of Birmingham
      • University of California, Davis
      • University of California
      • University of California Irvine
      • University of California Los Angeles
      • University of California San Francisco
      • University of Cambridge
      • University of Cologne
      • University of Connecticut
      • University of Maryland
      • University of Massachusetts, Amherst
      • University of Massachusetts
      • University of Minnesota
      • University of Oxford
      • University of Pittsburgh
      • University of Pittsburgh Medical Center
      • University of Queensland
      • University of Sydney
      • University of Tokyo
      • US Stem Cell Clinic
      • Vascugen
      • Vectalys
      • Vet-Stem
      • ViaCyte
      • ViraCyte
      • VistaGen Therapeutics
      • Vivo Biosciences
      • Waisman Biomanufacturing
      • Weill Cornell Medical College
      • W L Gore
      • Yale University
      • Yeda Research and Development Company
      • Yumanity Therapeutics
    • Stem Cell deals by stage of development
      • Discovery
      • Preclinical
      • Phase I
      • Phase II
      • Phase III
      • Regulatory
      • Marketed
    • Stem Cell deals by deal type
      • Asset purchase
      • Assignment
      • Co-development
      • Collaborative R&D
      • Contract Services
      • Co-promotion
      • CRADA
      • Cross-licensing
      • Development
      • Distribution
      • Equity purchase
      • Evaluation
      • Grant
      • Joint venture
      • Licensing
      • Manufacturing
      • Marketing
      • Option
      • Research
      • Settlement
      • Sub-license
      • Supply
    • Stem Cell deals by therapy area
      • Cardiovascular
      • Arrhythmia
      • Cardiomyopathy (heart muscle disease)
      • Congestive heart failure
      • Ischemic heart disease
      • Myocardial Infarction
      • Valvular heart disease
      • Central Nervous System
      • Motor Neurone Disease (Amyotrophic Lateral Sclerosis/Lou Gehrig's Disease)
      • Pain
      • Parkinson's disease
      • Spinal cord
      • Stroke
      • Traumatic Brain Injury
      • Hair disorders
      • Psoriasis
      • Wound healing
      • Wrinkles
      • Gastrointestinal
      • Crohn's disease
      • Genetic disorders
      • Cystic Fibrosis (CF)
      • Rare genetic disorders
      • Sickle cell disease
      • Genitourinary
      • Chronic kidney disease (CKD)
      • Hematology
      • Aesthetic procedures
      • Orthopedics
      • Transplantation
      • Immunology
      • AIDS
      • Graft versus host disease
      • Systemic lupus erythematosus
      • Infectives
      • Sepsis
      • HIV
      • Metabolic
      • Diabetes
      • Type 1
      • Type 2
      • Liver disease
      • Lysosomal storage disorders
      • Nutrition and vitamins
      • Musculoskeletal
      • Osteoarthritis
      • Muscular dystrophy
      • Preterm labour
      • Oncology
      • Bone cancer
      • Breast cancer
      • Leukemia
      • Acute lymphoblastic leukemia
      • Non Hodgkin's lymphoma
      • Melanoma
      • Metastases
      • Multiple myeloma
      • Solid tumors
      • Chemotherapy
      • Ophthalmics
      • Age-related macular degeneration
      • Blindness
      • Dry eye
      • Glaucoma
      • Retinal detachment
      • Retinopathy
      • Diabetic retinopathy
      • Orphan disease
      • Pediatrics
      • Psychiatry
      • Dementia
      • Alzheimers
      • Autism
      • Respiratory
      • Acute respiratory distress syndrome
      • Pneumonia
      • Hearing loss
      • Sexual Health
    • Deal type definitions
  • About Wildwood Ventures
    • Current Partnering
    • Current Agreements
    • Recent report titles from Current Partnering

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook